A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

This study is evaluating a new antibody-drug treatment called BL-B01D1 for women with gynecological cancers (such as ovarian, cervical, or endometrial cancer) that have returned or spread and no longer respond to standard therapies. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with a recurrent or metastatic gynecological cancer (confirmed by biopsy or pathology) - Standard treatments have failed, were not tolerated, or are not available for your cancer type - You have at least one measurable tumor on imaging - You are in good general health (ECOG score 0 or 1) - Your heart, blood, kidneys, and liver are functioning adequately - You are expected to live at least 3 months **You may NOT be eligible if:** - You have had certain prior heart treatments or have poor heart function - Side effects from prior cancer treatments have not resolved - You are pregnant or breastfeeding - Your urine protein levels are too high Talk to your doctor to see if this trial is right for you.